Annals of Surgery · 17 Nov 2026
Ex Vivo Lung Perfusion and Allograft Failure After Lung Transplantation
Sara Sakowitz, Syed Shahyan Bakhtiyar, Yas Sanaiha, Deep Mehta, Richard J. Shemin, Peyman Benharashh-index 17
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Objective: Ex vivo lung perfusion (EVLP) has been championed as a disruptive strategy to expand the lung transplantation (LT) donor pool, yet contemporary evidence remains limited. Using a real-world cohort, we emulated a randomized controlled trial (RCT) to characterize the causal effect of EVLP on post-LT survival. Methods: LT recipients ≥18 years were identified from the 2018–2025 Organ Procurement and Transplantation Network. Annual hospital LT volume was computed; centers in the top quartile (>54 LT/y) were designated high-volume centers (HVCs). Using target trial emulation with clone-censor-weight methodology, we simulated a pragmatic, open-label RCT comparing EVLP with standard allografts at HVCs and non-HVCs. Survival was evaluated using Kaplan-Meier and multivariable Cox models. Results: Among 20,627 LTs, 1419 (7%) received EVLP allografts. The proportion of EVLP allografts increased across all centers, from 5% in 2018 to 10% in 2024 and 8% in 2025 ( P trend <0.001). In the Lung Allocation Score era, LT using EVLP allografts yielded similar 2-year outcomes at HVC, but inferior outcomes at non-HVC. In the Composite Allocation Score period, however, EVLP was associated with significantly worse survival at non-HVC. In the emulated RCT among CAS-era recipients, EVLP remained independently associated with similar outcomes at HVC, but increased 2-year hazards of patient mortality (HR: 2.43, CI: 1.36–4.34, P =0.003) and allograft failure at non-HVC (HR: 2.52, CI: 1.31–4.84, P =0.005). Conclusions: EVLP was associated with comparable survival at HVC but inferior outcomes at non-HVC. These findings highlight the critical role of hospital context and center experience in determining the effectiveness and safety of EVLP and call for standardization of protocols across centers.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Peyman Benharash has the highest h-index among the authors (17).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.